Physician profile
Eric N Coffman
NPI 1457469330
$2,535.49
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $701 · 2020: $542 · 2021: $786 · 2022: $491 · 2023: $16.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $454.75 | 2019-2022 | |
| Gilead Sciences, INC. | $410.39 | 2019-2021 | |
| Abbvie INC. | $338.92 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $227.99 | 2019-2022 | |
| Uswm, LLC | $198.74 | 2021-2022 | |
| Mdd US Operations, LLC | $169.83 | 2019-2020 | |
| Orexo US, INC. | $165.85 | 2019-2023 | Zubsolv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.45 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $106.45 | 2019-2021 | |
| Zyla Life Sciences, INC. | $50.34 | 2019-2020 | |
| Allergan, INC. | $46.57 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $43.08 | 2021-2022 | |
| Glaxosmithkline, LLC. | $30.27 | 2019-2022 | |
| Indivior INC. | $26.93 | 2019-2022 | |
| Amgen INC. | $23.53 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $22.50 | 2021 | |
| Idorsia Pharmaceuticals US INC | $21.78 | 2022 | |
| Kaleo, INC. | $17.36 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.19 | 2019 | |
| Pfizer INC. | $14.71 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.31 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $13.07 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Coffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.